The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
A cohort of recipients of renal transplant after 2000 (N = 310) was prospectively screened on the day of transplantation and 1 month later for a panel of 11 thrombophilic factors to assess their effect on posttransplant outcomes. All patients received prophylactic acetylsalicylic acid, started before transplantation.The rate of thromboembolic events or acute rejection episodes during the first posttransplant year (primary composite endpoint) was 16.7% among patients free of thrombophilic factor (N = 60) and 17.2% in those with ≥1 thrombophilic factor (N = 250) (p > 0.99). The incidence of the primary endpoint was similar among patients free of thrombophilic factors and those with ≥2 (N = 135), or ≥3 (N = 53) factors (16.3% and 15.1% respectively; p = 1) and in patients who remained thrombophilic at 1 month (15.7%; p = 0.84). None of the individual thrombophilic factor present at the day of transplantation was associated with the primary endpoint. The incidence of cardiovascular events at 1‐year, serum creatinine at 1‐year, 4‐year actuarial graft and patient survival were not influenced by the presence of ≥1 thrombophilic factor at baseline (p = NS)....
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.